Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant
Status:
Active, not recruiting
Trial end date:
2022-12-29
Target enrollment:
Participant gender:
Summary
TAF treatment for HBV prophylaxis could lead to significant reduction in ALT and significant
improvement in renal function. However, data are scarce regarding to TAF monotherapy without
HBIG for HBV prophylaxis in post orthotopic liver transplant with HBV-related disease. This
study is based on a real-world, multi-center, prospective study to assess the effectiveness
and safety of TAF for HBV prophylaxis, which will fill in gaps with TAF monotherapy without
HBIG in post liver transplant.